INTELLIA THERAPEUTICS INC (NTLA)
US45826J1051 - Common Stock
NTLA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NTLA as it has an excellent financial health rating, but there are worries on the profitability. NTLA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NTLA had negative earnings in the past year.
In the past year NTLA has reported a negative cash flow from operations.
NTLA had negative earnings in each of the past 5 years.
In the past 5 years NTLA always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -63.82%, NTLA is doing worse than 61.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -79.06%, NTLA is in line with its industry, outperforming 51.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.82% | ||
| ROE | -79.06% | ||
| ROIC | N/A |
ROA(3y)-29.63%
ROA(5y)-27.7%
ROE(3y)-36.65%
ROE(5y)-34.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NTLA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTLA has been increased compared to 1 year ago.
NTLA has more shares outstanding than it did 5 years ago.
NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NTLA has an Altman-Z score of 2.00. This is not the best score and indicates that NTLA is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.00, NTLA is in the better half of the industry, outperforming 70.99% of the companies in the same industry.
There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 8.67 indicates that NTLA has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.67, NTLA is doing good in the industry, outperforming 75.60% of the companies in the same industry.
A Quick Ratio of 8.67 indicates that NTLA has no problem at all paying its short term obligations.
NTLA's Quick ratio of 8.67 is fine compared to the rest of the industry. NTLA outperforms 75.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.67 | ||
| Quick Ratio | 8.67 |
3. Growth
3.1 Past
NTLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.46%, which is quite good.
The Revenue has grown by 42.87% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 3.58% on average over the past years.
EPS 1Y (TTM)12.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-4.29%
Revenue 1Y (TTM)42.87%
Revenue growth 3Y-14.48%
Revenue growth 5Y3.58%
Revenue growth Q2Q167.32%
3.2 Future
The Earnings Per Share is expected to grow by 27.02% on average over the next years. This is a very strong growth
NTLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.32% yearly.
EPS Next Y-5.84%
EPS Next 2Y-1.73%
EPS Next 3Y-3.47%
EPS Next 5Y27.02%
Revenue Next Year-1.62%
Revenue Next 2Y3.04%
Revenue Next 3Y28.61%
Revenue Next 5Y103.32%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTLA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as NTLA's earnings are expected to decrease with -3.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.73%
EPS Next 3Y-3.47%
5. Dividend
5.1 Amount
NTLA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTELLIA THERAPEUTICS INC
NASDAQ:NTLA (5/2/2024, 5:14:37 PM)
After market: 23.28 +0.01 (+0.04%)23.27
+0.77 (+3.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.24B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -63.82% | ||
| ROE | -79.06% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.67 | ||
| Quick Ratio | 8.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)12.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)42.87%
Revenue growth 3Y-14.48%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y